Smither John W

Smither John W is listed in filings as Director at NewAmsterdam Pharma Company N.V.. This profile follows SEC Form 4 activity through Jan 9, 2026, including 9 public disclosures. Recent filings connect the profile to NewAmsterdam Pharma Company N.V. (NAMS) and Genelux Corporation (GNLX). The current snapshot covers public activity from Aug 5, 2024 to Jan 9, 2026. Reported amounts are shown as $840.1K to $77.7K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.